FDA: Dynavax's Heplisav effective against hepatitis B
Company stock rose 13% upon the news, closing Tuesday at $4.74. This marks the largest single-day jump since September 2011.
Dynavax does not yet have a product on the market, so Heplisav will be first should the FDA approve the vaccine Feb. 24, when the organization is scheduled to make a decision. The product could rake in an estimated $775 million in worldwide sales come 2020, Katherine Xu, an analyst with William Blair & Co., told Bloomberg.
In a study of about 2,400 patients ages 18 to 55, 95% of those who took two doses of Heplisav were protected from hepatitis B. By comparison, 81% of those who took three doses of Glaxo's Engerix-B were protected.
- see the FDA report (pdf)
- get more from Bloomberg
HepB vax Heplisav posts positive Ph3 data
Dynavax's Heplisav performs well, but shows product inconsistency
Diabetics under 60 should get hep B vaccine
Dynavax shares spike on promising Heplisav data